2. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  3. LXR
  4. Nagilactone B

Nagilactone B  (Synonyms: 竹柏内酯 B)

目录号: HY-N3216 纯度: ≥98.0%
COA 产品使用指南

摩尔计算器

Nagilactone B 是一种肝 X 受体 (LXR) 激动剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Nagilactone B Chemical Structure

Nagilactone B Chemical Structure

CAS No. : 19891-51-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥5400
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Nagilactone B 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Nagilactone B is a liver X receptor (LXR) agonist.

IC50 & Target

LXR[1]
体外研究
(In Vitro)

RAW264.7 cells are co-incubated with oxLDL (20 μg/mL) and Nagilactone B (0.02, 0.1, and 0.5 μM) for 24 h. Oil Red O (ORO) staining reveals significant lipid accumulation and foam cell formation in RAW264.7 cells following oxLDL treatment. Nagilactone B (NLB) significantly ameliorates intracellular lipid accumulation. ORO positive areas are reduced by 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001) in Nagilactone B (0.02, 0.1, and 0.5 μM)-treated groups, respectively. The effects of Nagilactone B are evaluated ton cholesterol efflux. Nagilactone B (0.02, 0.1, and 0.5 μM) markedly promotes cholesterol efflux to extracellular apolipoprotein A-I (apoA-I) and high density lipoprotein (HDL) with maximal 5.72- (P<0.05) and 2.34-fold (P<0.01), respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Nagilactone B 相关抗体:
体内研究
(In Vivo)

Nagilactone B (NLB) suppresses atherosclerosis in apoE-/- mice by inducing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) mediated cholesterol efflux in macrophages. Male apoE-deficient mice on C57BL/6J background receive Nagilactone B (10 and 30 mg/kg) for 12 weeks. Compared with the model group, Nagilactone B treatment (10 and 30 mg/kg) significantly reduces en face lesions of total aorta areas. Six-week-old male apoE-/- mice on an HFD are randomized to receive Atorvastatin (10 mg/kg/day), Nagilactone B (10 and 30 mg/kg/day), or CMC-Na for 12 weeks. Mice on chow diet are administered CMC-Na as the normal diet control group. En face aortic lesion areas are evaluated with Sudan IV staining and lesion areas in the aortic sinus monitored via ORO staining. Atherosclerosis developes slowly in the normal diet group, whereas lesions in the HFD model group are significantly increased in en face aortas. Nagilactone B treatment (10 and 30 mg/kg/day) significantly reduces en face aortic lesions, compared with the HFD group by 54.96±10.06% (P<0.01), 71.50±15.37% (P<0.001) in both NLB (L) and NLB (H) groups. In particular, Nagilactone B markedly attenuates atherosclerotic plaque lesion areas in the aortic arch aorta, thoracic aorta, and abdominal aorta [P<0.01 in NLB (H) group][1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

364.39

Formula

C19H24O7
CAS 号
性状

固体

颜色

White to off-white

中文名称

竹柏内酯 B
结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
纯度 & 产品资料

纯度: ≥98.0%

COA (272 KB) HNMR (134 KB) RP-HPLC (131 KB)

产品使用指南 (1538 KB)
参考文献
Cell Assay
[1]

RAW264.7 cells are plated into 12-well plates at 3×105 cells per well. After 12 h, cells are co-incubated with oxLDL (20 μg/mL) with or without Nagilactone B (0.02, 0.1, 0.5 μM) in DMEM for 24 h. At the end of the treatment period, cells are washed twice with PBS, fixed with 4% paraformaldehyde, and stained by filtered 0.5% ORO. Images are obtained via DP70 microscopy from at least six randomly selected fields for each condition. Data are analysed with Image-Pro Plus 6.0 software. The ratio of foam cells is calculated as the percentage of stained to total cell area[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Mice[1]
ApoE-/- mice at 6 weeks of age on a C57BL/6J background are randomly divided into five groups [normal diet, model, Atorvastatin, NLB (L), and NLB (H) groups]. Atorvastatin and NLB are dissolved in CMC-Na before administered. Mice on the normal diet receive carboxymethylcellulose sodium (CMC-Na) as the negative control group. Mice on a high-fat diet (HFD) (0.15% cholesterol and 18% fat) are administered CMC-Na or Atorvastatin (10 mg/kg) or Nagilactone B [10 and 30 mg/kg, as NLB (L) and NLB (H), respectively] daily in an intragastric manner for 12 weeks. Body weight and food intake are monitored[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

Nagilactone B 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nagilactone B19891-51-1竹柏内酯 BLXRLiver X receptorInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Nagilactone B
目录号：
HY-N3216
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z